SCHEMBL4648345

SCHEMBL4648345

CSc1ccc(C(=O)Nc2ccnc(Cl)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
RXFP1 Q9HBX9 1/20 0.48
PLK1 P53350 1/20 0.47
KMT2A Q03164 5/20 0.47
PPARG P37231 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
NR2E3 Q9Y5X4 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
POLB P06746 1/20 0.47
GRM5 P41594 3/20 0.45
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
TP53 P04637 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
MEN1 O00255 2/20 0.41
CYP1A2 P05177 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28687700 0.81 GRM5 (0.59) L3MBTL1RXFP1KMT2APPARGTDP1
SCHEMBL7207983 0.81 KMT2A (0.62) L3MBTL1RXFP1KMT2APPARGTDP1
SCHEMBL14033011 0.78 L3MBTL1 (0.46) L3MBTL1RXFP1KMT2APPARGTDP1
SCHEMBL10655608 0.76 RAB9A (0.46) L3MBTL1RXFP1PLK1KMT2AGRM5
SCHEMBL17541672 0.74 PTK2 (0.51) L3MBTL1KMT2APOLBGRM5MEN1
SCHEMBL2244112 0.73 NPC1 (0.64) PLK1KMT2ATDP1RAB9ANPC1
SCHEMBL15881317 0.72 GRM5 (0.48) L3MBTL1RXFP1KMT2APPARGTDP1
SCHEMBL4644302 0.71 RAB9A (0.58) KMT2APOLBRAB9ANPC1TP53
SCHEMBL17617988 0.71 TYK2 (0.48) L3MBTL1GRM5SMN1; SMN2
SCHEMBL28160772 0.71 GRM5 (0.44) L3MBTL1KMT2APPARGTDP1NR2E3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675830-A4 HETEROCYCLIC AMIDES AND SULFONAMIDES SCIOS INC (US) 2008-08-20 EP disclosed
US-20060199821-A1 Heterocyclic amides and sulfonamides SCIOS, INC. (US) 2006-09-07 US disclosed
EP-1675830-A2 HETEROCYCLIC AMIDES AND SULFONAMIDES SCIOS INC. (US) 2006-07-05 EP disclosed
WO-2005033072-A2 HETEROCYCLIC AMIDES AND SULFONAMIDES SCIOS INC. (US) 2005-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199821-A1 Heterocyclic amides and sulfonamides MAP4K2, MAP3K8, MAP3K2 L3MBTL1 3403/4885RXFP1 3827/4885PLK1 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.